Cargando…

Antiviral protection by antibodies targeting the glycan cap of Ebola virus glycoprotein requires activation of the complement system

Antibodies to Ebola virus glycoprotein (EBOV GP) represent an important correlate of the vaccine efficiency and infection survival. Both neutralization and some of the Fc-mediated effects are known to contribute the protection conferred by antibodies of various epitope specificities. At the same tim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bukreyev, Alexander, Ilinykh, Philipp, Huang, Kai, Gunn, Bronwyn, Kuzmina, Natalia, Gilchuk, Pavlo, Alter, Galit, Crowe, James
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Journal Experts 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10153373/ https://www.ncbi.nlm.nih.gov/pubmed/37131834 http://dx.doi.org/10.21203/rs.3.rs-2765936/v1

Ejemplares similares

Asymmetric antiviral effects of ebolavirus antibodies targeting glycoprotein stem and glycan cap
por: Ilinykh, Philipp A., et al.
Publicado: (2018)

Convergence of a common solution for broad ebolavirus neutralization by glycan cap-directed human antibodies
por: Murin, Charles D., et al.
Publicado: (2021)

Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma
por: Gilchuk, Pavlo, et al.
Publicado: (2021)

BROADLY NEUTRALIZING ANTIBODIES FROM HUMAN SURVIVORS TARGET A CONSERVED SITE IN THE EBOLA VIRUS GLYCOPROTEIN HR2/MPER REGION
por: Flyak, Andrew I., et al.
Publicado: (2018)

Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein
por: Gilchuk, Pavlo, et al.
Publicado: (2018)

Exploiting glycan topography for computational design of Env glycoprotein antigenicity
por: Yu, Wen-Han, et al.
Publicado: (2018)

Cross-reactive neutralizing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalk
por: King, Liam B., et al.
Publicado: (2019)

Species-Specific Evolution of Ebola Virus during Replication in Human and Bat Cells
por: Whitfield, Zachary J., et al.
Publicado: (2020)

Epitope-focused immunogen design based on the ebolavirus glycoprotein HR2-MPER region
por: Schoeder, Clara T., et al.
Publicado: (2022)

Antibodies against the Ebola virus soluble glycoprotein are associated with long-term vaccine-mediated protection of non-human primates
por: Gunn, Bronwyn M., et al.
Publicado: (2023)

Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy
por: Balzarini, Jan
Publicado: (2007)

Staufen1 Interacts with Multiple Components of the Ebola Virus Ribonucleoprotein and Enhances Viral RNA Synthesis
por: Fang, Jingru, et al.
Publicado: (2018)

Blocking of ebolavirus spread through intercellular connections by an MPER-specific antibody depends on BST2/tetherin
por: Santos, Rodrigo I., et al.
Publicado: (2023)

Systematic analysis of human antibody response to ebolavirus glycoprotein shows high prevalence of neutralizing public clonotypes
por: Chen, Elaine C., et al.
Publicado: (2023)

Modified vaccinia Ankara vaccine expressing Marburg virus-like particles protects guinea pigs from lethal Marburg virus infection
por: Malherbe, Delphine C., et al.
Publicado: (2020)

Analysis of a Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebolavirus Neutralization
por: Gilchuk, Pavlo, et al.
Publicado: (2020)

Requirements within the Ebola Viral Glycoprotein for Tetherin Antagonism
por: Vande Burgt, Nathan H., et al.
Publicado: (2015)

Ross River virus envelope glycans contribute to disease through activation of the host complement system
por: Gunn, Bronwyn M., et al.
Publicado: (2018)

Ebola virus glycoprotein directly triggers T lymphocyte death despite of the lack of infection
por: Iampietro, Mathieu, et al.
Publicado: (2017)

Ebola VP40 in Exosomes Can Cause Immune Cell Dysfunction
por: Pleet, Michelle L., et al.
Publicado: (2016)

Glycan analysis of therapeutic glycoproteins
por: Zhang, Lei, et al.
Publicado: (2015)

The complexity of glycoprotein-derived glycans
por: VLIEGENTHART, Johannes F. G.
Publicado: (2017)

Survivors of Ebola Virus Disease Develop Polyfunctional Antibody Responses
por: Gunn, Bronwyn M, et al.
Publicado: (2020)

Corrigendum: Ebola VP40 in Exosomes Can Cause Immune Cell Dysfunction
por: Pleet, Michelle L., et al.
Publicado: (2018)

The alternative cap-binding complex is required for antiviral defense in vivo
por: Gebhardt, Anna, et al.
Publicado: (2019)

Structural Biology Illuminates Molecular Determinants of Broad Ebolavirus Neutralization by Human Antibodies for Pan-Ebolavirus Therapeutic Development
por: Murin, Charles D., et al.
Publicado: (2022)

Ubiquitination of Ebola virus VP35 at lysine 309 regulates viral transcription and assembly
por: van Tol, Sarah, et al.
Publicado: (2022)

The Ebola Virus Glycoprotein and HIV-1 Vpu Employ Different Strategies to Counteract the Antiviral Factor Tetherin
por: Kühl, Annika, et al.
Publicado: (2011)

Disabling of lymphocyte immune response by Ebola virus
por: Younan, Patrick, et al.
Publicado: (2018)

A novel pre-fusion conformation-specific neutralizing epitope on the respiratory syncytial virus fusion protein
por: Mousa, Jarrod J., et al.
Publicado: (2017)

Recombinant Antibodies to the Ebola Virus Glycoprotein
por: Panina, A. A., et al.
Publicado: (2017)

Antibody Repertoires to the Same Ebola Vaccine Antigen Are Differentially Affected by Vaccine Vectors
por: Meyer, Michelle, et al.
Publicado: (2018)

Glycan shield of the ebolavirus envelope glycoprotein GP
por: Peng, Weiwei, et al.
Publicado: (2022)

Dendritic Cells/Macrophages-Targeting Feature of Ebola Glycoprotein and its Potential as Immunological Facilitator for Antiviral Vaccine Approach
por: Olukitibi, Titus Abiola, et al.
Publicado: (2019)

Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies
por: Evgin, Laura, et al.
Publicado: (2016)

Ebola and Marburg virus VP35 coiled-coil validated as antiviral target by tripartite split-GFP complementation
por: Zinzula, Luca, et al.
Publicado: (2022)

Toremifene interacts with and destabilizes the Ebola virus glycoprotein
por: Zhao, Yuguang, et al.
Publicado: (2016)

Associations Between Antibody Fc-Mediated Effector Functions and Long-Term Sequelae in Ebola Virus Survivors
por: Paquin-Proulx, Dominic, et al.
Publicado: (2021)

Function and 3D Structure of the N-Glycans on Glycoproteins
por: Nagae, Masamichi, et al.
Publicado: (2012)

Ebolavirus Species-Specific Interferon Antagonism Mediated by VP24
por: Ramanathan, Palaniappan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cp450cqgfti44re2qp8f2etesj